Statut réglementaire: Composé en développement, pas encore approuvé
IUPAC Name: N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide;methylsulfinylmethane
EC Number: 629-898-8
Molecular Weight: 693.5
Chemical Formula: C₂₈H₂₉FIN₅O₅S
CAS Number: 1187431-43-1
Application: API oncologique pour thérapie combinée avec inhibiteur de MEK (cancers à mutation BRAF, gliome)
Type de formulation: Solvate de DMSO (forme polymorphe)
Pays d'origine: Europe (fabricant d'API basé dans l'UE)
Status: Pipeline
Development phase: Under development
Therapeutic cat.: Oncology
Polymorphic form: DMSO solvate
OEB No.: 5
Samples: Q4 2024

Autres informations

Description supplémentaire:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.